Compass Pathways (NASDAQ:CMPS), a unicorn company in the psychedelics space, has been granted its fourth patent by the US Patent and Trademark Office. The company’s flagship phase 2 research ...

Shares from psychedelics unicorn Compass Pathways (NASDAQ: CMPS) are soaring in anticipation of the data being created by the company’s phase 2 trial with the psychedelic psilocybin.

Psychedelics biotech company Compass Pathways (NASDAQ: CMPS) has purchased an intellectual property portfolio that includes patent applications for a variety of psychedelic and empathogenic ...